SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma

Safety, tolerability, pharmacokinetics and pharmacodynamics of the anti‐CD38 cytolytic antibody TAK‐079 in healthy subjects

(2020) Eric R. Fedyk et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma

(2020) Ilaria Saltarella et al.   Cells

Isatuximab: First Approval

(2020) Sohita Dhillon   DRUGS

Harnessing the immune system via FcγR function in immune therapy: a pathway to next‐gen mAbs

(2020) Alicia M Chenoweth et al.   IMMUNOLOGY AND CELL BIOLOGY

A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma

(2020) Joseph Mikhael et al.   LEUKEMIA

Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting

(2020) Domenico Viola et al.   LEUKEMIA

Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis

(2020) Meletios A. Dimopoulos et al.   LEUKEMIA

Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab

(2020) Tineke Casneuf et al.   LEUKEMIA

MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1–2a trial

(2020) Marc S Raab et al.   Lancet Haematology

Resistance Mechanisms towards CD38−Directed Antibody Therapy in Multiple Myeloma

(2020) Laurens E. Franssen et al.   Journal of Clinical Medicine

Targeting CD38 is lethal to Breg-like chronic lymphocytic leukemia cells and Tregs, but restores CD8+ T-cell responses

(2020) Alak Manna et al.   Blood Advances

Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells

(2020) Chen Zhu et al.   Frontiers in Immunology

Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma

(2019) Thomas Martin et al.   Blood Cancer Journal

Daratumumab: A Review in Combination Therapy for Transplant-Ineligible Newly Diagnosed Multiple Myeloma

(2019) Yahiya Y. Syed   DRUGS

The Mechanism Of Action Of The Anti-CD38 Monoclonal Antibody Isatuximab In Multiple Myelmoa

(2019) Laura Moreno et al.   CLINICAL CANCER RESEARCH

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

(2019) Thierry Facon et al.   NEW ENGLAND JOURNAL OF MEDICINE

In vivo vaccination effect in multiple myeloma patients treated with the monoclonal antibody isatuximab

(2019) Djordje Atanackovic et al.   LEUKEMIA

The Relationship between Baseline Biomarkers and Efficacy of Isatuximab in Combination with Pomalidomide and Dexamethasone in RRMM: Insights from Phase 1 and Phase 3 Studies

(2019) Paul G. Richardson et al.   BLOOD

Genetic Variation in Low-To-Medium-Affinity Fcγ Receptors: Functional Consequences, Disease Associations, and Opportunities for Personalized Medicine

(2019) Sietse Q. Nagelkerke et al.   Frontiers in Immunology

Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab

(2019) Thomas G. Martin et al.   Cells

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

(2019) Michel Attal et al.   LANCET

Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma

(2018) Niels W. C. J. van de Donk et al.   BRITISH JOURNAL OF HAEMATOLOGY

Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis

(2018) Marjorie Pick et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia

(2018) Jyoti Naik et al.   HAEMATOLOGICA

CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance

(2018) Niels W.C.J. van de Donk et al.   Frontiers in Immunology

IgG Fc engineering to modulate antibody effector functions

(2017) Xinhua Wang et al.   Protein & Cell

Roles and Modalities of Ectonucleotidases in Remodeling the Multiple Myeloma Niche

(2017) Antonella Chillemi et al.   Frontiers in Immunology

Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs

(2017) Gianfranco Pittari et al.   Frontiers in Immunology

Predictive Value of FcR Polymorphisms

(2017) Riccardo Dolcetti   JAMA Oncology

Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM

(2016) A. Jakubowiak et al.   BLOOD

Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma

(2016) J. Krejcik et al.   BLOOD

Daratumumab: First Global Approval

(2016) Kate McKeage   DRUGS

The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor–Mediated Cross-Linking

(2016) Marije B. Overdijk et al.   JOURNAL OF IMMUNOLOGY

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

(2016) Sagar Lonial et al.   LANCET

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

(2016) Meletios A. Dimopoulos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunosurveillance and therapy of multiple myeloma are CD226 dependent

(2015) Camille Guillerey et al.   JOURNAL OF CLINICAL INVESTIGATION

SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide

(2015) H Jiang et al.   LEUKEMIA

Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab

(2015) I S Nijhof et al.   LEUKEMIA

Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma

(2015) Marije B Overdijk et al.   mAbs

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

(2015) Henk M. Lokhorst et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Anti-CD40 and Anti-IL-23 Monoclonal Antibody Therapy Effectively Suppresses Tumor Growth and Metastases

(2014) B. von Scheidt et al.   CANCER RESEARCH

SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies

(2014) J. Deckert et al.   CLINICAL CANCER RESEARCH

Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide

(2014) I. S. Nijhof et al.   HAEMATOLOGICA

A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer

(2013) James D Mellor et al.   Journal of Hematology & Oncology

Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy

(2012) M. Chesi et al.   BLOOD

Mouse model recapitulating human Fc  receptor structural and functional diversity

(2012) P. Smith et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Multiple Myeloma

(2011) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab

(2010) M. S. van der Veer et al.   HAEMATOLOGICA

Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors

(2010) M. de Weers et al.   JOURNAL OF IMMUNOLOGY

Specificity and affinity of human Fc  receptors and their polymorphic variants for human IgG subclasses

(2008) P. Bruhns et al.   BLOOD

AID-Dependent Activation of a MYC Transgene Induces Multiple Myeloma in a Conditional Mouse Model of Post-Germinal Center Malignancies

(2008) Marta Chesi et al.   CANCER CELL

Potent In vitro and In vivo Activity of an Fc-Engineered Anti-CD19 Monoclonal Antibody against Lymphoma and Leukemia

(2008) H. M. Horton et al.   CANCER RESEARCH

Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer

(2008) Antonino Musolino et al.   JOURNAL OF CLINICAL ONCOLOGY